Daily Stock Pick â€” January 22, 2026

FOLD â€“ Amicus Therapeutics

News: BioMarin signed a definitive allâ€‘cash deal to acquire Amicus for $14.50/share; closing targeted for Q2 2026 (regulatory and shareholder approvals pending).

Score (0â€“1000): 650

ADVICE: Buy

Certainty: 74%

Forecast image URL: https://stockscan.io/stocks/FOLD/forecast

Verifier note: Lowâ€‘risk mergerâ€‘arb spread with downside cushioned by profitable, growing rareâ€‘disease franchise; 2025 guidance targets positive GAAP in H2 and midâ€‘80% gross margins. Sources: investors.biomarin.com (deal terms/close timing), ir.amicusrx.com (revenue growth, profitability guidance). ([investors.biomarin.com](https://investors.biomarin.com/news/news-details/2025/BioMarin-to-Acquire-Amicus-Therapeutics-for-4-8-Billion-Expanding-Position-as-a-Leader-in-Rare-Diseases-Accelerating-Revenue-Growth-and-Strengthening-Financial-Outlook/default.aspx?utm_source=openai))

---
**Legend**
ğŸŸ¢ğŸŸ¢ğŸŸ¢ **Ultra Strong Buy** â€” Score > 800 â†’ â€œGuaranteed high returnâ€
ğŸŸ¢ **Strong Buy** â€” Score > 700 â†’ â€œAmazing Chancesâ€
ğŸŸ¡ **Buy** â€” Score â‰ˆ 600 â†’ â€œGreat Chancesâ€
ğŸ”´ **Ignore** â€” Score < 599 â†’ â€œIgnoreâ€

